Expand all sections

Dostarlimab

Jemperli

Extended indication Extension of indication to include in combination with platinum -containing chemotherapy the treatme
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Dostarlimab
Domain Oncology
Reason of inclusion Indication extension
Main indication Ovarian cancer
Extended indication Extension of indication to include in combination with platinum -containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability -high (MSI -H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy
Proprietary name Jemperli
Manufacturer GSK
Portfolio holder GSK
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date December 2023
Expected Registration October 2024
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.